All content for MediCom Oncology Clinical Pearls Podcasts is the property of MediCom Oncology and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Dr. Perl provides a brief summary of what is on the horizon for FLT3 inhibitors in AML.
Has MRD testing become a standard of care in multiple myeloma?
MediCom Oncology Clinical Pearls Podcasts
3 minutes 22 seconds
8 years ago
Has MRD testing become a standard of care in multiple myeloma?
Dr. Ruben Niesvizky discusses MRD testing and how it has become a standard of care in multiple myeloma, as well as future directions in MRD testing that will improve outcomes in these patients.
MediCom Oncology Clinical Pearls Podcasts
Dr. Perl provides a brief summary of what is on the horizon for FLT3 inhibitors in AML.
